Skip to main content

Genmab

Genmab A/S is a Danish biotechnology company specializing in the discovery and development of human antibody therapeutics for oncology treatments. The company leverages proprietary antibody technology platforms, including DuoBody, HexaBody, and Hexect, to generate targeted bispecific antibodies. Revenue is primarily driven by royalty streams from global sales of Darzalex (daratumumab) licensed to Janssen, milestone payments, and commercial sales of co-developed therapies like Epkinly. Key end markets encompass specialized oncology networks, hematology departments, and hospital systems in North America, Europe, and Asia. Genmab holds a leading international market position as an innovator in targeted cancer antibody therapies with multiple commercialized partner drugs. The company is headquartered in Copenhagen, Denmark, and its shares are listed on Nasdaq Copenhagen and Nasdaq in the US under the ticker GMAB.

67 of the funds FundTelligence covers report a position in Genmab.

Sector
Health Care
Country
Denmark
Funds holding it
67
Exposure themes
Cancer, Treatment, Women's Health

Funds holding Genmab

Showing the 8 largest of 67 funds holding it.

Loading...